{"id":"usual-care-inhaled-glucocorticosteroids","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Oral candidiasis (thrush)"},{"rate":"5-10","effect":"Hoarseness"},{"rate":"5-15","effect":"Tremor (from beta-agonist co-administration)"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Dysphonia"}]},"_chembl":{"chemblId":"CHEMBL545","moleculeType":"Small molecule","molecularWeight":"46.07"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glucocorticosteroids are potent anti-inflammatory agents that work by translocating to the nucleus and modulating gene expression of inflammatory mediators. When inhaled directly into the lungs, they achieve high local concentrations while minimizing systemic exposure, reducing airway inflammation, mucus production, and bronchial hyperresponsiveness in asthma and COPD.","oneSentence":"Inhaled glucocorticosteroids reduce airway inflammation by binding to glucocorticoid receptors in lung tissue, suppressing inflammatory cytokine production and immune cell activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:07.406Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT00404547","phase":"PHASE4","title":"Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-11","conditions":"Asthma","enrollment":1121}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Usual Care Inhaled Glucocorticosteroids","genericName":"Usual Care Inhaled Glucocorticosteroids","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhaled glucocorticosteroids reduce airway inflammation by binding to glucocorticoid receptors in lung tissue, suppressing inflammatory cytokine production and immune cell activation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}